Lowe’s Companies Inc. (NYSE: LOW) topped market expectations on revenue for the first quarter of 2019 but earnings fell shy of forecasts, causing shares to sink 9% in premarket hours on Wednesday.
Total sales were $17.7 billion, up 2.2% from the same period last year. Comparable sales grew 3.5% while comparable sales for the US home improvement business rose 4.2%.
On a GAAP basis, the company reported net income of $1 billion, or $1.31 per share, compared to $988 million, or $1.19 per share, in the year-ago period. Adjusted EPS was $1.22.
Lowe’s had planned to exit its Mexico retail operations by selling the operating business. However, after an extensive market evaluation, the company decided to sell the assets of the business instead. This decision resulted in an $82 million tax benefit in the first quarter, which offset $12 million of pre-tax operating costs for the Mexico retail operations.
Marvin R. Ellison, Lowe’s president and CEO said, “We are taking the necessary actions to more systematically analyze and implement retail price changes to mitigate cost pressure. Our recent acquisition of the Retail Analytics platform from Boomerang Commerce will also assist in modernizing and digitizing our approach to pricing. We are still in the early stages of our transformation, and with the changes we are putting in place, we expect to deliver improved gross margin performance over the balance of the year.”
As of May 3, 2019, Lowe’s operated 2,002 home improvement and hardware stores in the US and Canada, representing 208.8 million square feet of retail selling space.
For fiscal year 2019, total sales are expected to increase approx. 2% while comparable sales are expected to increase approx. 3%. GAAP EPS is expected to be $5.54 to $5.74 and adjusted EPS is expected to be $5.45 to $5.65.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on